- Lobbying
- Lobbying by Ridgeback Biotherapeutics
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Kelly Childress | Rep. Shimkus, LA; Rep. Rogers, Health Policy Adviser Rep. Shimkus, LA; Rep. Mike Rogers, Health Policy Advisor |
Andrew Hawkins | Rep. Mike Rogers, LA, LD, Chief of Staff Rep. Mike Rogers, LA, LD, COS |
Michael Woody | Rep. Berry, LA; Sen. Harkin, LA; HELP Committee |
David Mohler | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q2 Report
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Type of Issue
Registration
Issue(s) they said they’d lobby about: Legislative and regulatory issues related to the development of vaccines and therapeutics for orphan and infectious diseases..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate